Peptide Regulatory Status Tracker
Where 24 peptides stand with the U.S. FDA - the 503A compounding categories, the 7 substances the advisory committee voted on July 23–24, 2026 (it recommended 6 for the 503A list and rejected one), and the GLP-1 503B proposal. Every row links to its primary Federal Register or FDA.gov source. Filter it, search it, and download the data.
Short answer: only 5 of the 24 peptides in this tracker are FDA-approved finished drugs. The rest fall into three groups: substances the Pharmacy Compounding Advisory Committee voted on at its July 23–24, 2026 meeting, where the outcome is a non-binding recommendation rather than an approval; substances already placed on an FDA 503A category list; and substances on no current 503A list at all. The distinction that trips up most patients: lawful compounding under section 503A and FDA drug approval are separate legal questions - a peptide can be legal to compound for an individual patient while remaining an unapproved drug. This tracker records the current status of each substance against the FDA 503A category list updated May 14, 2026, separating finished-drug approval from compounding eligibility into different columns. It also tracks the FDA proposal to permit GLP-1 bulk compounding by 503B outsourcing facilities - a different regulatory track from the 503A list for traditional compounding pharmacies. Physician-reviewed as of October 30, 2026.
“Is this peptide FDA-approved? Is it legal to compound?” is one of the hardest questions to answer honestly, because the rules are changing month to month and most of what circulates online is either a retailer’s sales copy or a law firm’s prose. This tracker does one thing: it records the current regulatory status of each peptide from primary U.S. government documents, with the source linked on every row.
The conservative spine matters. Being on the 503A list is not the same as FDA approval. Only 5 of the substances below are FDA-approved finished drugs. Most of the “wellness” peptides - BPC-157, CJC-1295, ipamorelin - are on no current 503A list at all; their nominations were withdrawn. And a favorable July 2026 advisory-committee vote is a recommendation, not an approval - the list itself has not changed. Neither does the HHS interim policy of October 28, 2026: it is a decision not to take enforcement action against licensed compounding of six of those peptides, not an approval or a listing. For what the committee decided, see Did the FDA approve BPC-157?; for the underlying biochemistry, see Is It a Peptide?; for the deeper compounding-law explainer, see FDA peptide compounding status.

The Tracker
Filter by status, search any peptide or brand, and export the full dataset as CSV or JSON (CC BY 4.0 - free to reuse with attribution). Status reflects the FDA 503A category list updated May 14, 2026 and Federal Register notices verified October 30, 2026.
Showing 24 of 24 substances
| Substance | Regulatory status | What that means | Most recent event | Source |
|---|---|---|---|---|
| BPC-157PCAC July 23, 2026 · recommended for inclusion 8–6 (1 abstention) · use evaluated: Ulcerative colitis | PCAC recommended for inclusionreported | Still not FDA-approved and still not on the 503A bulks list. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee voted 8–6 (1 abstention) to recommend adding it to the 503A list for the use it evaluated. The recommendation is non-binding and the list is unchanged. Under an interim HHS policy issued October 28, 2026, HHS does not intend to take enforcement action against licensed pharmacies and physicians that compound it as an injection (subcutaneous or intramuscular), an oral form or a topical form for a patient-specific prescription, under the policy’s conditions, while FDA completes rulemaking. That is enforcement discretion, not approval. | Covered by the HHS interim enforcement-discretion policy for 503A compounding, October 28, 2026 (Federal Register notice published October 30, 2026). Before that: PCAC recommended inclusion on the 503A bulks list, 8–6 with 1 abstention, July 23, 2026 (tally per contemporaneous reporting of the public meeting; FDA minutes not yet posted). | Fed. Register (FDA-2025-N-6895)FDA.govFDA.govFed. Register (HHS-OASH-2026-0496) |
| EpitalonepithalonPCAC July 24, 2026 · recommended for inclusion 7–4 · use evaluated: Insomnia | PCAC recommended for inclusionreported | Still not FDA-approved and still not on the 503A bulks list. On July 24, 2026 the FDA Pharmacy Compounding Advisory Committee voted 7–4 to recommend adding it to the 503A list for the use it evaluated. The recommendation is non-binding and the list is unchanged. Under an interim HHS policy issued October 28, 2026, HHS does not intend to take enforcement action against licensed pharmacies and physicians that compound it as a subcutaneous or intramuscular injection given in intermittent courses for a patient-specific prescription, under the policy’s conditions, while FDA completes rulemaking. That is enforcement discretion, not approval. | Covered by the HHS interim enforcement-discretion policy for 503A compounding, October 28, 2026 (Federal Register notice published October 30, 2026). Before that: PCAC recommended inclusion on the 503A bulks list, 7–4, July 24, 2026 (tally per contemporaneous reporting of the public meeting; FDA minutes not yet posted). | Fed. Register (FDA-2025-N-6895)FDA.govFed. Register (HHS-OASH-2026-0496) |
| KPVPCAC July 23, 2026 · recommended for inclusion 8–6 (1 abstention) · use evaluated: Wound healing and inflammatory conditions | PCAC recommended for inclusionreported | Still not FDA-approved and still not on the 503A bulks list. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee voted 8–6 (1 abstention) to recommend adding it to the 503A list for the use it evaluated. The recommendation is non-binding and the list is unchanged. Under an interim HHS policy issued October 28, 2026, HHS does not intend to take enforcement action against licensed pharmacies and physicians that compound it as a topical or oral form for a patient-specific prescription, under the policy’s conditions, while FDA completes rulemaking. That is enforcement discretion, not approval. | Covered by the HHS interim enforcement-discretion policy for 503A compounding, October 28, 2026 (Federal Register notice published October 30, 2026). Before that: PCAC recommended inclusion on the 503A bulks list, 8–6 with 1 abstention, July 23, 2026 (tally per contemporaneous reporting of the public meeting; FDA minutes not yet posted). | Fed. Register (FDA-2025-N-6895)FDA.govFed. Register (HHS-OASH-2026-0496) |
| MOTS-cPCAC July 23, 2026 · recommended for inclusion 7–5 (2 abstentions) · use evaluated: Obesity and osteoporosis | PCAC recommended for inclusionreported | Still not FDA-approved and still not on the 503A bulks list. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee voted 7–5 (2 abstentions) to recommend adding it to the 503A list for the use it evaluated. The recommendation is non-binding and the list is unchanged. Under an interim HHS policy issued October 28, 2026, HHS does not intend to take enforcement action against licensed pharmacies and physicians that compound it as a subcutaneous or intramuscular injection for a patient-specific prescription, under the policy’s conditions, while FDA completes rulemaking. That is enforcement discretion, not approval. | Covered by the HHS interim enforcement-discretion policy for 503A compounding, October 28, 2026 (Federal Register notice published October 30, 2026). Before that: PCAC recommended inclusion on the 503A bulks list, 7–5 with 2 abstentions, July 23, 2026 (tally per contemporaneous reporting of the public meeting; FDA minutes not yet posted). | Fed. Register (FDA-2025-N-6895)FDA.govFed. Register (HHS-OASH-2026-0496) |
| SemaxPCAC July 24, 2026 · recommended for inclusion 8–5 · use evaluated: Cerebral ischemia, migraine, and trigeminal neuralgia | PCAC recommended for inclusionreported | Still not FDA-approved in the United States and still not on the 503A bulks list. On July 24, 2026 the FDA Pharmacy Compounding Advisory Committee voted 8–5 to recommend adding it to the 503A list for the use it evaluated. The recommendation is non-binding and the list is unchanged. Under an interim HHS policy issued October 28, 2026, HHS does not intend to take enforcement action against licensed pharmacies and physicians that compound it as an intranasal product for a patient-specific prescription, under the policy’s conditions, while FDA completes rulemaking. That is enforcement discretion, not approval. | Covered by the HHS interim enforcement-discretion policy for 503A compounding, October 28, 2026 (Federal Register notice published October 30, 2026). Before that: PCAC recommended inclusion on the 503A bulks list, 8–5, July 24, 2026 (tally per contemporaneous reporting of the public meeting; FDA minutes not yet posted). | Fed. Register (FDA-2025-N-6895)FDA.govFed. Register (HHS-OASH-2026-0496) |
| TB-500thymosin beta-4 fragmentPCAC July 23, 2026 · recommended for inclusion 8–6 (1 abstention) · use evaluated: Wound healing | PCAC recommended for inclusionreported | Still not FDA-approved and still not on the 503A bulks list. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee voted 8–6 (1 abstention) to recommend adding it to the 503A list for the use it evaluated. The recommendation is non-binding and the list is unchanged. Under an interim HHS policy issued October 28, 2026, HHS does not intend to take enforcement action against licensed pharmacies and physicians that compound it as a subcutaneous or intramuscular injection for a patient-specific prescription, under the policy’s conditions, while FDA completes rulemaking. That is enforcement discretion, not approval. | Covered by the HHS interim enforcement-discretion policy for 503A compounding, October 28, 2026 (Federal Register notice published October 30, 2026). Before that: PCAC recommended inclusion on the 503A bulks list, 8–6 with 1 abstention, July 23, 2026 (tally per contemporaneous reporting of the public meeting; FDA minutes not yet posted). | Fed. Register (FDA-2025-N-6895)FDA.govFed. Register (HHS-OASH-2026-0496) |
| Emideltidedelta sleep-inducing peptide (DSIP)PCAC July 24, 2026 · recommended against inclusion 6–7 · use evaluated: Opioid withdrawal, chronic insomnia, and narcolepsy | PCAC recommended against inclusionreported | Not FDA-approved and not on the 503A bulks list. On July 24, 2026 the FDA Pharmacy Compounding Advisory Committee voted 6–7 against recommending it for the 503A list - the only substance of the seven heard that the committee declined to recommend. The recommendation is non-binding, but nothing about the vote moves it toward compounding eligibility. | PCAC recommended against inclusion on the 503A bulks list, 6–7, July 24, 2026. Tally per contemporaneous reporting of the public meeting; FDA minutes not yet posted. | Fed. Register (FDA-2025-N-6895)FDA.gov |
| GHK-Cu (topical / non-injectable)copper peptide | 503A Category 1 | Non-injectable GHK-Cu is on Category 1 (under evaluation; may be used in compounding while FDA completes its review). The injectable route is NOT - see the injectable row. | Removed from Category 1 on April 22, 2026 when nominations were withdrawn; after a May 5, 2026 clarification that only the injectable route was withdrawn, the non-injectable form was added back to Category 1. FDA intends to consult the PCAC on GHK-Cu before the end of February 2027. | FDA.gov |
| Vasoactive intestinal peptideVIP | 503A Category 1 | On Category 1 (under evaluation; may be used in compounding while FDA completes its review). Not FDA-approved as a finished drug. | Listed in Category 1 on the FDA 503A category list updated May 14, 2026. | FDA.gov |
| IbutamorenMK-677 (a growth-hormone secretagogue, often marketed alongside peptides) | 503A Category 2 | On Category 2 - FDA identified a significant safety risk, so it should not be used in 503A compounding. Not FDA-approved. (Chemically a small molecule, not a peptide, but frequently sold under the "peptide" umbrella.) | Listed in Category 2 (as ibutamoren mesylate) on the FDA 503A category list updated May 14, 2026. | FDA.gov |
| Kisspeptin-10 | 503A Category 2 | On Category 2 - FDA identified a significant safety risk, so it should not be used in 503A compounding. Not FDA-approved. | Listed in Category 2 on the FDA 503A category list updated May 14, 2026. | FDA.gov |
| CibinetideARA-290 | 503A Category 3 | On Category 3 - nominated without adequate supporting information for FDA to evaluate. Not FDA-approved. | Listed in Category 3 on the FDA 503A category list updated May 14, 2026. | FDA.gov |
| AOD-9604 | Not on the 503A list | Not on any current 503A category list and not FDA-approved. Its nomination for the 503A bulks list was withdrawn. | Not present on the FDA 503A category list updated May 14, 2026. | FDA.gov |
| CJC-1295 | Not on the 503A list | Not on any current 503A category list and not FDA-approved. Its nomination for the 503A bulks list was withdrawn. | Not present on the FDA 503A category list updated May 14, 2026. | FDA.gov |
| GHK-Cu (injectable)copper peptide | Not on the 503A list | The injectable route of GHK-Cu is not on any 503A category list; its nomination was withdrawn and not reinstated. Not FDA-approved. | Injectable-route nomination withdrawn April 22, 2026; not added back (clarified May 5, 2026). | FDA.gov |
| Ipamorelin | Not on the 503A list | Not on any current 503A category list and not FDA-approved. Its nomination for the 503A bulks list was withdrawn. | Not present on the FDA 503A category list updated May 14, 2026. | FDA.gov |
| Selank | Not on the 503A list | Not on any current 503A category list and not FDA-approved. Its nomination for the 503A bulks list was withdrawn. | Not present on the FDA 503A category list updated May 14, 2026. | FDA.gov |
| Sermorelin | Not on the 503A list | A sermorelin finished drug (Geref) was FDA-approved in 1990 and 1997 and discontinued in 2008; no approved sermorelin product is marketed now. Sermorelin is not on any current 503A category list. Its compounding eligibility rests on prior-approval history and is not settled here. | March 4, 2013: FDA determined Geref was not withdrawn from sale for reasons of safety or effectiveness. Not present on the FDA 503A category list updated May 14, 2026. | Fed. Register (FDA-2012-P-1071)FDA.govFDA.gov |
| Thymosin alpha-1 | Not on the 503A list | Not on any current 503A category list and not FDA-approved in the U.S. (approved in some other countries). Its U.S. nomination for the 503A bulks list was withdrawn. | Not present on the FDA 503A category list updated May 14, 2026. | FDA.gov |
| BremelanotidePT-141, Vyleesi | FDA-approved drugreported | The finished drug Vyleesi is FDA-approved. Compounded "PT-141" is not the approved product and is not FDA-approved. | Vyleesi FDA-approved finished drug (approval reported 2019). | FDA.gov |
| LiraglutideVictoza, Saxenda | FDA-approved drug | FDA-approved as branded finished drugs. Separately, FDA has proposed NOT to add liraglutide to the 503B outsourcing-facility bulks list; the comment period on that notice runs through July 30, 2026. | Named in the FDA 503B clinical-need notice proposing exclusion (Federal Register, May 1, 2026; comment period extended to July 30, 2026). | Fed. Register (FDA-2018-N-3240)Fed. Register (FDA-2018-N-3240) |
| SemaglutideOzempic, Wegovy, Rybelsus | FDA-approved drug | FDA-approved as branded finished drugs. Separately, FDA has proposed NOT to add semaglutide to the 503B outsourcing-facility bulks list; the comment period on that notice runs through July 30, 2026. Shortage-based compounding has ended. | Named in the FDA 503B clinical-need notice proposing exclusion (Federal Register, May 1, 2026; comment period extended to July 30, 2026). | Fed. Register (FDA-2018-N-3240)Fed. Register (FDA-2018-N-3240) |
| TesamorelinEgrifta | FDA-approved drug | FDA-approved as a finished drug (Egrifta), a growth-hormone-releasing-hormone analog. This is an approved product, distinct from the 503A compounding lists. | Egrifta approved November 10, 2010 (Theratechnologies, application 022505). | FDA.gov |
| TirzepatideMounjaro, Zepbound | FDA-approved drug | FDA-approved as branded finished drugs. Separately, FDA has proposed NOT to add tirzepatide to the 503B outsourcing-facility bulks list; the comment period on that notice runs through July 30, 2026. Shortage-based compounding has ended. | Named in the FDA 503B clinical-need notice proposing exclusion (Federal Register, May 1, 2026; comment period extended to July 30, 2026). | Fed. Register (FDA-2018-N-3240)Fed. Register (FDA-2018-N-3240) |
How this is built: Rows marked as primary were read directly from the Federal Register full text (PCAC meeting notice, docket FDA-2025-N-6895; and the 503B clinical-need notice, docket FDA-2018-N-3240) and the FDA 503A category list PDF. Rows marked “reported” rest on secondary reporting and are labeled as such. FDA lists change - always confirm against the linked source at time of use.
Scope & compliance: This is regulatory-status information, not medical or legal advice. It contains no doses and makes no efficacy claims. Nothing here should be read as encouragement to use any unapproved substance.
What the PCAC Decided on July 23–24, 2026
The FDA Pharmacy Compounding Advisory Committee (PCAC) met over two days and voted on seven peptides nominated for the 503A bulks list. It recommended six of them for inclusion and rejected one. On July 23: BPC-157 8–6 (1 abstention), KPV 8–6 (1 abstention), TB-500 8–6 (1 abstention), and MOTS-c 7–5 (2 abstentions). On July 24: epitalon 7–4 and semax 8–5 were recommended, while emideltide (delta sleep-inducing peptide) was voted down 6–7. FDA’s own review scientists had argued against easing restrictions, in part because several of these substances are not chemically well-characterized. The public docket is FDA-2025-N-6895.
Two things this vote was not. It was not FDA approval - all seven remain unapproved drugs, and approval is a separate, finished-drug pathway. And it was not the lifting of a ban: these substances came off 503A Category 2 back in April 2026 when their nominations were withdrawn. This week’s vote was about adding them to the 503A list, a later and different step. The recommendation is non-binding, and only FDA rulemaking can add a substance to the list; the October 28 enforcement policy below is a separate step. Full breakdown: Did the FDA approve BPC-157?
Vote tallies are from contemporaneous reporting of the public meeting; FDA has not yet posted minutes. The seven affected rows in the tracker are therefore labelled “reported” rather than primary-sourced; they will be upgraded when the official minutes publish.
Where the reporting disagrees: Epitalon - Reporting on this tally differs. STAT published 7–4; Regulatory Focus (RAPS) published 7–5 with one abstention. The figure shown here follows STAT. FDA minutes will settle it. Emideltide - Both STAT and Regulatory Focus (RAPS) report the 6–7 outcome, but RAPS also reports one abstention that STAT does not mention. The figure shown here follows STAT.
What HHS Changed on October 28, 2026
On October 28, 2026 the Secretary of Health and Human Services issued an interim enforcement-discretion policy for six of the seven peptides the PCAC heard. Until FDA finishes rulemaking on each substance, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound them for a patient-specific prescription, as long as every condition in the policy is met. Emideltide, the one peptide the committee voted down, is not covered. The six, with the dosage forms the policy allows:
- BPC-157: compounded as an injection (subcutaneous or intramuscular), an oral form or a topical form
- KPV: compounded as a topical or oral form
- TB-500: compounded as a subcutaneous or intramuscular injection
- MOTS-c: compounded as a subcutaneous or intramuscular injection
- Semax: compounded as an intranasal product
- Epitalon: compounded as a subcutaneous or intramuscular injection given in intermittent courses
The other conditions include an ingredient made by an FDA-registered manufacturer and backed by a certificate of analysis, one peptide per product, and reporting of serious adverse events and quality problems to FDA. This is not FDA approval. The policy itself says compounded drugs are not FDA-approved, none of the six has been added to the 503A bulks list, and HHS says it may revisit the policy if a safety signal or product-quality problem appears. It does not cover “research use only” products sold online. Notice of the policy was published in the Federal Register on October 30, 2026, with public comments open until November 13, 2026 (docket HHS-OASH-2026-0496).
Which peptides are on FDA’s Category 1 list?
Category 1 is FDA’s list of bulk substances under evaluation for 503A compounding; a substance on it may generally be used in compounding while FDA finishes its review. FDA’s list updated May 14, 2026 names 49 substances in Category 1, and most are not peptides (vitamins, plant extracts, NAD and similar). The peptides on it are:
- GHK-Cu (topical / non-injectable), also called copper peptide
- Vasoactive intestinal peptide, also called VIP
- Glutathione, a three-amino-acid peptide usually discussed as an antioxidant
- Alanyl-L-glutamine, a two-amino-acid peptide used as a glutamine source
The wellness peptides people usually ask about, including BPC-157, TB-500, CJC-1295 and ipamorelin, are not on Category 1 or any other 503A category. One peptide, kisspeptin-10, is on Category 2, the list of substances FDA says raise significant safety risks. Ibutamoren (MK-677), often sold alongside peptides, is on Category 2 too, but it is not a peptide. Category 1 is not FDA approval. Check the FDA 503A categories page for the current list.
Frequently Asked Questions
Is BPC-157 FDA-approved or legal to compound in 2026?
No. BPC-157 is not FDA-approved, and as of the FDA 503A category list updated May 14, 2026 it is not on the 503A bulks list. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee voted 8–6 (1 abstention) to recommend adding it to that list for the use it evaluated, ulcerative colitis. That recommendation is non-binding and is not approval: FDA must still complete formal rulemaking before the list itself changes. Since October 28, 2026, an interim HHS policy has said HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157 for a patient-specific prescription under the policy’s conditions while that rulemaking runs. So licensed compounding on a prescription that meets those conditions is not expected to draw federal enforcement for now, but BPC-157 is still unapproved, the list itself has not changed, and state pharmacy rules still apply.
What did the FDA advisory committee decide in July 2026?
The FDA Pharmacy Compounding Advisory Committee met July 23–24, 2026 and voted on seven nominated peptides. It recommended six for addition to the 503A bulks list - BPC-157 (8–6, 1 abstention), KPV (8–6, 1 abstention), TB-500 (8–6, 1 abstention) and MOTS-c (7–5, 2 abstentions) on July 23; epitalon (7–4) and semax (8–5) on July 24. It voted 6–7 against emideltide (DSIP), the only rejection. Every recommendation is non-binding - FDA must still complete formal rulemaking, and all seven substances remain unapproved drugs. Public docket FDA-2025-N-6895. Vote tallies are from contemporaneous reporting of the public meeting; FDA minutes are not yet posted. On October 28, 2026 HHS issued an interim enforcement-discretion policy covering the six recommended peptides, not emideltide; see the next question.
What did HHS change for peptides on October 28, 2026?
On October 28, 2026 HHS issued an interim policy: until FDA finishes rulemaking on each substance, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 for a patient-specific prescription under the policy’s conditions. That is enforcement discretion, not FDA approval: none of the six is FDA-approved or on the 503A bulks list. The policy limits each peptide to listed dosage forms and requires an ingredient from an FDA-registered manufacturer with a certificate of analysis, one peptide per product, and reporting of serious adverse events to FDA. HHS says it may revisit the policy if a safety signal or product-quality problem appears. Notice of the policy was published in the Federal Register on October 30, 2026 (docket HHS-OASH-2026-0496).
What does "503A Category 1, 2, or 3" mean?
These are the FDA's working categories for bulk substances nominated for use in pharmacy compounding under section 503A. Category 1 means "under evaluation" - a substance may generally be used in compounding while FDA finishes its review. Category 2 means FDA identified a significant safety risk, so it should not be compounded. Category 3 means the nomination lacked adequate supporting information. A substance on none of these lists was either never nominated or had its nomination withdrawn.
Can compounding pharmacies still make semaglutide or tirzepatide?
Generally no. Compounding of the GLP-1 drugs was permitted only while they were on the FDA drug-shortage list; those shortages resolved, ending that basis. Separately, in a Federal Register notice published May 1, 2026 (docket FDA-2018-N-3240), FDA proposed NOT to add semaglutide, tirzepatide, or liraglutide to the 503B outsourcing-facility bulks list. The comment period on that notice was extended to July 30, 2026.
Which peptides are FDA-approved?
Only a handful of peptide DRUGS are FDA-approved as finished products, and that is a completely different pathway from the compounding lists. Approved examples include semaglutide, tirzepatide, and liraglutide (GLP-1 drugs), tesamorelin (Egrifta), and bremelanotide (Vyleesi). Most peptides marketed by wellness brands - BPC-157, CJC-1295, ipamorelin, and so on - are not FDA-approved.
Is this legal advice?
No. This tracker reports the regulatory status of peptides as recorded in public FDA and Federal Register documents. It is educational information, not medical or legal advice, and the underlying FDA lists change. Verify the current status against the linked primary source before relying on it, and consult a licensed professional for your situation.
Primary Sources
- FDA - Pharmacy Compounding Advisory Committee; Notice of Meeting (July 23–24, 2026). Federal Register, published April 16, 2026. - Docket FDA-2025-N-6895.
- FDA - Pharmacy Compounding Advisory Committee: meeting materials, roster, minutes, and webcast archive (July 23–24, 2026 meeting).
- FDA - Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Category 1 / 2 / 3 list). Updated May 14, 2026.
- FDA - Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (program hub).
- FDA - List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (proposes NOT to include semaglutide, tirzepatide, liraglutide). Federal Register, published May 1, 2026. - Docket FDA-2018-N-3240.
- FDA - Extension of Comment Period for the 503B clinical-need notice (comment period extended to July 30, 2026). Federal Register, published June 26, 2026. - Docket FDA-2018-N-3240.
- FDA - Human Drug Compounding Laws (conditions for the 503A and 503B exemptions).
- FDA - Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, published March 4, 2013. - Docket FDA-2012-P-1071.
- FDA - Drugs@FDA: EGRIFTA (tesamorelin acetate), application 022505, Theratechnologies.
- HHS - Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (issued October 28, 2026). Notice of availability, Federal Register, published October 30, 2026. - Docket HHS-OASH-2026-0496.
Reviewed by Dr. Charles Kamen, MD - LiveNow Longevity, Las Vegas. This reference is educational and is not medical or legal advice.
Ready to start your longevity care?
Book your $88 evaluation with Dr. Kamen today, online, by phone, or by text.
Prefer to talk? Call (702) 808-2650 or text us to book.
Also serving Henderson - or explore semaglutide weight loss in Las Vegas.
